<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481272</url>
  </required_header>
  <id_info>
    <org_study_id>PLRG8 (OMB114361)</org_study_id>
    <secondary_id>2010-023568-42</secondary_id>
    <nct_id>NCT01481272</nct_id>
  </id_info>
  <brief_title>Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients</brief_title>
  <acronym>PLRG8</acronym>
  <official_title>A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is expected that addition of anti-CD20 antibody - ofatumumab would enhance the activity of
      the etoposide+ifosphamide with mesna+cytarabine+methotrexate+lenograstim or filgrastim (IVAC)
      regimen. This study is planned to determine the efficacy and safety of ofatumumab in
      combination with IVAC chemotherapy in patients with CD20 positive diffuse large B cell
      lymphoma progressing or relapsed after prior R-CHOP chemotherapy not suitable for Autologous
      Stem Cell Transplant (ASCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the Overall Response Rate (ORR) = Complete Response
      (CR) + Partial Response (PR) in adult Diffuse Large B Cell Lymphoma (DLBCL) patients
      progressing or relapsed after prior R-CHOP treatment not suitable for ASCT treated with
      O-IVAC salvage chemotherapy regimen. The secondary objective is the evaluation of
      progression-free survival (PFS), event-free survival (EFS), overall survival (OS), safety and
      tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months post-therapy</time_frame>
    <description>Complete response + partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 month post-therapy</time_frame>
    <description>Staying free of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>12 month post-therapy</time_frame>
    <description>Staying free of event such as disease progression, relapse, death, starting new anticancer therapy, patient's refusal to continue study treatment, Serious Adverse Event that causes discontinuation of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months post-therapy</time_frame>
    <description>Time since entering the study till death of any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 months post-therapy</time_frame>
    <description>Reporting Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>O-IVAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab Etoposide Ifosfamide Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Colony Stimulating Factor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Arzerra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamid</intervention_name>
    <description>1500mg/m2 or 1000mg/m2 (patients &gt;/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>300mg/m2 or 200mg/m2 (patients &gt;/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients &gt;/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2g/m2 or 0,5-1g/m2 (patients &gt;/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Cytosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Methotrexat Ebeve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leukovorin</intervention_name>
    <description>15mg, po 24 hours after methotrexate it</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Folinic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-Colony Stimulating Factor</intervention_name>
    <description>5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC&gt;1.0x109/l</description>
    <arm_group_label>O-IVAC</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients under consideration for participation in this study must meet all of the
             following inclusion criteria:

          -  Histologically confirmed CD20 positive diffuse large B-cell lymphoma.

          -  Progressing or relapsed following prior treatment including but not limited to
             rituximab-CHOP chemotherapy regimen.

          -  Not suitable for ASCT (age &gt; 60 years, PS ≥ 2, prior ASCT as a part of the previous
             treatment for DLBCL, and/or other medical conditions that unable the patients to
             undergo the ASCT, e.g. NYHA II, creatinine clearance &lt; 50 mL/min).

          -  Age ≥ 18 years.

          -  ECOG/ WHO performance status grades 0 - 3.

          -  Resolution of toxicities from previous therapy to grade ≤ 1.

          -  Written signed and dated informed consent prior to any study procedures being
             performed.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to study treatments.

          -  Prior treatment with anti-CD20 monoclonal antibodies with the exception of rituximab.

          -  Screening laboratory values:

               -  platelets &lt; 75 x 109/L (unless due to DLBCL involvement of the bone marrow),

               -  neutrophils &lt; 1.5 x 109/L (unless due to DLBCL involvement of the bone marrow),

               -  creatinine &gt; 2.0 times upper normal limit (unless normal creatinine clearance),

               -  total bilirubin &gt;1.5 times upper normal limit (unless due to DLBCL involvement of
                  liver or a known history of Gilbert's disease),

               -  ALT &gt; 2.5 times upper normal limit (unless due to DLBCL involvement of liver),

               -  alkaline phosphatase &gt; 2.5 times upper normal limit (unless due to DLBCL
                  involvement of the liver or bone marrow).

          -  Subjects who have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
             chronic liver disease per investigator assessment).

          -  Treatment with any known non-marketed drug substance or experimental therapy within 5
             terminal half lives or 4 weeks prior to enrolment, whichever is longer, or currently
             participating in any other interventional clinical study.

          -  Other past or current malignancy. Subjects who have been free of malignancy for at
             least 5 years, or have a history of completely resected non-melanoma skin cancer, or
             successfully treated in situ carcinoma are eligible.

          -  Chronic or current infectious disease requiring systemic antibiotics, antifungal, or
             antiviral treatment such as, but not limited to, chronic renal infection, chronic
             chest infection with bronchiectasis, tuberculosis and active Hepatitis C.

          -  History of significant cerebrovascular disease in the past 6 months or ongoing event
             with active symptoms or sequel.

          -  Known HIV positive.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within six months prior to randomization, congestive heart failure (NYHA
             III-IV), and arrhythmia unless controlled by therapy, with the exception of extra
             systoles or minor conduction abnormalities.

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
             psychiatric disease which in the opinion of the investigator may represent a risk for
             the patient.

          -  Positive serology for Hepatitis B (HB).

          -  Positive serology for hepatitis C (HC).

          -  Pregnant or lactating women. Women of childbearing potential must have a negative
             pregnancy test at screening.

          -  Women of childbearing potential, including women whose last menstrual period was less
             than one year prior to screening, unable or unwilling to use adequate contraception
             from study start to one year after the last dose of protocol therapy.

          -  Male subjects unable or unwilling to use adequate contraception methods from study
             start to one year after the last dose of protocol therapy.

          -  Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Walewski, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>CENTRUM ONKOLOGII - INSTYTUT im. Marii Skłodowskiej-Curie ul. W.K. Roentgena 5, 02-781 Warszawa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krzysztof Warzocha, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instytut Hematologii i Transfuzjologii, 02-776 Warszawa ul. Indiry Gandhi 14</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Hellmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Hematologii i Tranplantologii, Uniwersyteckie Centrum Medyczne, ul. Dębinki 7, 80-952 Gdańsk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Pluta, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. Bronisława Markiewicza, ul. ks. Bielawskiego 18, 36-200 Brzozów</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Lange, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dolnośląskie Centrum Transplantacji Komórkowych, 53-439 Wrocław, ul. Grabiszyńska105</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wanda Knopinska-Posluszny, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddz. Hematologii, Samodzielny Publiczny ZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie; ul.Wojska Polskiego 37, 10-228 Olsztyn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Giebel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Transplantacji Szpiku i Onkohematologii, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie w Gliwicach; al. Wybrzeże Armii Krajowej 15, 44-101 Gliwice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan M Zaucha, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddz. Onkologii i Radioterapii, Szpital Morski im. PCK; ul. Powstania Styczniowego 1, 81-519 Gdynia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dolnośląskie Centrum Transplantacji Komórkowych</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Istytut im. M.Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. Bronisława Markiewicza</name>
      <address>
        <city>Brzozów</city>
        <state>Podkarpackie</state>
        <zip>16-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Cenrum Medyczne</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK Oddz. Onkologii i Radioterapii</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku i Onkohematologii; Centrum Onkologii Instytut im. M.Sklodowskiej-Curie, Oddz. w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddz. Hematologii, Samodzielny Publiczny ZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-Mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Salvage therapy in DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

